Bourne Partners Strategic Capital

The firm relies on its affiliated advisory practice, which executes sell-side and capital-markets mandates for healthcare companies across the pharma and services spectrum. This advisory flow has closed over 200 transactions since 2006 and provides a proprietary window into founder-owned companies often before a competitive auction begins. The firm also receives direct inbound interest from business owners seeking a capital partner with sector operating knowledge.

The fund focuses on lower-middle-market businesses generating between $2 million and $15 million in EBITDA. Sector emphasis is on specialty pharma, pharma outsourcing and contract manufacturing, and healthcare services. The firm typically writes equity checks for growth capital, recapitalizations, or complete buyouts and favors situations where its advisory background adds operational value beyond the capital deployed.

It operates as a hybrid merchant bank. One side of the firm runs an active investment-banking practice executing M&A and capital-raising mandates for healthcare clients. The other side, Bourne Partners Strategic Capital, invests proprietary capital directly into companies. This dual structure is intentional — the advisory work informs the investment practice and generates deal flow, while the investment returns supplement the firm's recurring advisory revenue.

Firm founder Banks Bourne is the central figure in both the advisory and investment practices. Public disclosures and Securities and Exchange Commission filings for the Strategic Capital funds list Bourne as a managing member with ultimate investment authority. The firm operates with an intentionally lean team structure, meaning senior advisory professionals commonly participate in investment-committee deliberations.

The primary investment geography is the United States, with a concentration in the Southeast and Mid-Atlantic regions where the firm's advisory relationships are densest. Canada is the second market of focus. Western Europe is evaluated opportunistically, particularly for assets in the pharma-services supply chain that complement existing portfolio companies or advisory clients.